DE2425764A1 - Tabletten - Google Patents
TablettenInfo
- Publication number
- DE2425764A1 DE2425764A1 DE19742425764 DE2425764A DE2425764A1 DE 2425764 A1 DE2425764 A1 DE 2425764A1 DE 19742425764 DE19742425764 DE 19742425764 DE 2425764 A DE2425764 A DE 2425764A DE 2425764 A1 DE2425764 A1 DE 2425764A1
- Authority
- DE
- Germany
- Prior art keywords
- tablets
- nicotinic acid
- release
- active ingredient
- continuous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 56
- 239000004480 active ingredient Substances 0.000 claims description 48
- 229960003512 nicotinic acid Drugs 0.000 claims description 28
- 235000001968 nicotinic acid Nutrition 0.000 claims description 28
- 239000011664 nicotinic acid Substances 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 18
- 239000008187 granular material Substances 0.000 claims description 15
- 239000000654 additive Substances 0.000 claims description 8
- 230000000996 additive effect Effects 0.000 claims description 8
- 239000008014 pharmaceutical binder Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 229920000945 Amylopectin Polymers 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 239000008019 pharmaceutical lubricant Substances 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 5
- 238000002844 melting Methods 0.000 claims description 5
- 230000008018 melting Effects 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 150000003377 silicon compounds Chemical class 0.000 claims description 5
- 235000003441 saturated fatty acids Nutrition 0.000 claims description 4
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 3
- 238000012377 drug delivery Methods 0.000 claims description 3
- 229910021485 fumed silica Inorganic materials 0.000 claims description 2
- 239000003826 tablet Substances 0.000 description 69
- 239000013543 active substance Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 229940060367 inert ingredients Drugs 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- QHZLMUACJMDIAE-UHFFFAOYSA-N 1-monopalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- GFAZGHREJPXDMH-UHFFFAOYSA-N 1,3-dipalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCC GFAZGHREJPXDMH-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 208000002141 Pellagra Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000003084 food emulsifier Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- UHUSDOQQWJGJQS-UHFFFAOYSA-N glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 description 1
- JEJLGIQLPYYGEE-UHFFFAOYSA-N glycerol dipalmitate Natural products CCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCC JEJLGIQLPYYGEE-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000012243 magnesium silicates Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920003073 plasdone K polymer Polymers 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000010181 polygamy Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36444373A | 1973-05-29 | 1973-05-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2425764A1 true DE2425764A1 (de) | 1975-01-02 |
Family
ID=23434551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19742425764 Pending DE2425764A1 (de) | 1973-05-29 | 1974-05-28 | Tabletten |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JPS5031022A (enrdf_load_stackoverflow) |
| DE (1) | DE2425764A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2231365B1 (enrdf_load_stackoverflow) |
| GB (1) | GB1422768A (enrdf_load_stackoverflow) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3527852A1 (de) * | 1984-08-03 | 1986-02-20 | Nippon Shinyaku Co., Ltd., Kyoto | Pharmazeutische zubereitung und verfahren zu ihrer herstellung |
| US4797288A (en) * | 1984-10-05 | 1989-01-10 | Warner-Lambert Company | Novel drug delivery system |
| US4804548A (en) * | 1984-10-05 | 1989-02-14 | Warner-Lambert Company | Novel sweetener delivery systems |
| US4828857A (en) * | 1984-10-05 | 1989-05-09 | Warner-Lambert Company | Novel sweetener delivery systems |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2904310A1 (de) * | 1979-02-05 | 1980-08-07 | Boehringer Mannheim Gmbh | Formlinge mit retardierter wirkstofffreisetzung und verfahren zu deren herstellung |
| JPS5974374U (ja) * | 1982-11-11 | 1984-05-19 | セイコーインスツルメンツ株式会社 | 携帯時計の文字板保持構造 |
| US5268181A (en) * | 1989-04-13 | 1993-12-07 | Upsher-Smith Laboratories, Inc. | Method of using niacin to control nocturnal cholesterol synthesis |
| ES2096103T3 (es) * | 1992-01-13 | 1997-03-01 | Pfizer | Preparacion de comprimidos de resistencia incrementada. |
| US10105358B2 (en) * | 2013-05-09 | 2018-10-23 | Zeenar Enterprises Pty Ltd | Niacin formulation |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1617593A1 (de) * | 1965-10-12 | 1971-04-29 | Leo Pharm Prod Ltd | Verfahren zur Herstellung von Tabletten oder Pillen |
-
1974
- 1974-05-27 JP JP5890874A patent/JPS5031022A/ja active Pending
- 1974-05-27 FR FR7418230A patent/FR2231365B1/fr not_active Expired
- 1974-05-28 DE DE19742425764 patent/DE2425764A1/de active Pending
- 1974-05-28 GB GB2353574A patent/GB1422768A/en not_active Expired
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3527852A1 (de) * | 1984-08-03 | 1986-02-20 | Nippon Shinyaku Co., Ltd., Kyoto | Pharmazeutische zubereitung und verfahren zu ihrer herstellung |
| US4797288A (en) * | 1984-10-05 | 1989-01-10 | Warner-Lambert Company | Novel drug delivery system |
| US4804548A (en) * | 1984-10-05 | 1989-02-14 | Warner-Lambert Company | Novel sweetener delivery systems |
| US4828857A (en) * | 1984-10-05 | 1989-05-09 | Warner-Lambert Company | Novel sweetener delivery systems |
Also Published As
| Publication number | Publication date |
|---|---|
| GB1422768A (en) | 1976-01-28 |
| FR2231365A1 (enrdf_load_stackoverflow) | 1974-12-27 |
| JPS5031022A (enrdf_load_stackoverflow) | 1975-03-27 |
| FR2231365B1 (enrdf_load_stackoverflow) | 1977-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3875705T2 (de) | Carbidopa-levodopa-zusammensetzung mit gesteuerter freigabe. | |
| DE2224534C3 (de) | Pharmazeutisches Präparat mit langsamer Wirkstoffabgabe | |
| DE68902531T2 (de) | Dispergierbare zubereitung. | |
| DE1292783B (de) | Verfahren zum Herstellen einer Tablette mit Depotwirkung | |
| DE1467906A1 (de) | Verfahren zur Herstellung von sich langsam loesenden Tabletten | |
| DE2128461A1 (de) | Pharmazeutisches Präparat | |
| DE2721603A1 (de) | Beschichtete koernchen aus alkalimetallsalzen der polyacrylsaeure und verfahren zu ihrer herstellung | |
| DE2706660A1 (de) | Ascorbinsaeure enthaltende granulate und verfahren zu ihrer herstellung | |
| WO2003101430A1 (de) | Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung | |
| EP0469328A1 (de) | Verfahren zur Herstellung klein dimensionierter Formkörper mit hohem Etofibrat-Gehalt und kontrollierter Wirkstoff-Freisetzung, deren Verwendung und daraus bestehende oral verabreichbare Applikationsformen | |
| DE2425764A1 (de) | Tabletten | |
| DE69401502T2 (de) | Arzneizubereitung zum Herstellen eines stabilisierten Pulvers das eine Kombination aus Acetylsalicylsäure und Metoclopramid als Wirkstoff enthält | |
| DE68905613T2 (de) | Pharmazeutische Zubereitung. | |
| DE1088192B (de) | Verfahren zur Herstellung von tablettierbaren oder direkt verwendbaren Arzneimittelgranulaten mit einstellbaren Freigabeeigenschaften | |
| DE68914683T2 (de) | Arzneimittelzusammensetzung für die schnelle verabreichung des aktiven bestandteils, der aus einer festen dispersion und einem oberflächenaktiven mittel besteht. | |
| EP0208144B1 (de) | Ambroxol oder bromhexin enthaltendes arzneimittelgranulat | |
| CH683824A5 (de) | Zusammensetzung als Mittel zur Behandlung von Entzündungen. | |
| DE69002186T2 (de) | Kalziumpantothenatzusammensetzung. | |
| DE1935879B2 (de) | Verfahren zur Herstellung eines pharmazeutischen Lithium-Präparates | |
| DE2439538B2 (de) | Verfahren zur Herstellung von oral zu verabreichenden Arzneimitteln mit verzögerter Wirkungsfreigabe | |
| DE2148391A1 (de) | Arzneimittel mit verlängerter Wirk stoffabgabe | |
| DE2448119A1 (de) | Pharmazeutische zubereitungen | |
| DE1925919C3 (de) | Tablette für die gleichmäßige Freisetzung eines Arzneimittels | |
| DE1219176B (de) | Verfahren zur Herstellung von Arzneipraeparaten mit verzoegerter Wirkstoffabgabe | |
| DE1492123A1 (de) | Verfahren zur Herstellung von Arzneipraeparaten in Tablettenform |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OHJ | Non-payment of the annual fee |